通过替代性处理形成的粉样蛋白 通过交叉连接减轻阿尔茨海默氏症的粉样β毒性
Ariel J Kuhn1, Ka Chan1, Maria Sajimon1
1Department of Chemistry and Biochemistry, University of California, Santa Cruz, Santa Cruz, California 95064, United States.
Journal of the American Chemical Society
|January 18, 2024
概括
在阿尔茨海默氏症中,粉样蛋白-α (Aα) 形成粉样纤维,并影响粉样蛋白-β (Aβ) 聚合. 这种相互作用降低了Aβ毒性,表明Aα
科学领域:
- 神经科学
- 生物化学
- 结构生物学
背景情况:
- 阿尔茨海默病 (AD) 的发病包括粉样蛋白聚合,主要是粉样β (Aβ).
- 针对Aβ的治疗策略表现出有限的成功,突出显示需要考虑粉体沉积异质性.
- 已确定Aβ片段的氨基 (Aα) 是一种快速聚合的,可以产生Aβ聚合.
研究的目的:
- 在阿尔茨海默病的背景下阐明粉胺-阿尔法 (Aα) 的生物物理和生物特性.
- 确定Aα纤维细胞形成的结构基础及其与Aβ的相互作用.
- 研究Aα对Aβ聚合和毒性的影响.
主要方法:
- 低温电子显微镜 (cryo-EM) 用于确定Aα粉状纤维的结构.
- 核磁共振 (NMR) 光谱研究溶液中的Aα和Aβ相互作用.
- 与纯Aβ聚合物相比,评估协聚Aα和Aβ的毒性.
主要成果:
- 获得了Aα粉状纤维素的第一个冷EM结构,证实了其纤维化性质.
- 与纯Aβ聚合物相比,Aα被证明可以诱导Aβ粉体聚合物的形成,其毒性降低.
- 核磁共振研究提供了Aα和Aβ在溶液中的特定相互作用的见解,证明了低度的协同组合.
结论:
- 粉胺-α (Aα) 是一种可以与粉胺-β (Aβ) 共组合的纤维化.
- Aα和Aβ的联合组合改变了Aβ的生物效应,显著降低了总体毒性.
- 这些发现强调了在阿尔茨海默病病理和治疗发展中考虑Aα的重要性,敦促重新评估其意义.
相关概念视频
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Alzheimer's Disease: Overview
490
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
490


